X hits on this document

326 views

0 shares

0 downloads

0 comments

62 / 71

Vaccination

A vaccine against EBV which prevents primary EBV infection should be able to control both BL and NPC.

Such a vaccine must be given early in life. Such a vaccine would also be useful in seronegative organ transplant recipients and those developing severe IM, such as the male offspring of X-linked proliferative syndrome carriers.

The vaccine should not preferably be a subunit vaccine since there is a danger that a live vaccine may still have tumorigenic properties.

The antigen chosen for vaccine development is the MA antigen gp 340/220 as antibodies against this antigen are virus neutralizing.

This vaccine is being tried in Africa.

Document info
Document views326
Page views326
Page last viewedFri Dec 09 12:02:35 UTC 2016
Pages71
Paragraphs617
Words5071

Comments